Watch Youtube Videos

Tags : mp3 evolution avril lavigne nightmare chemical guitar akon timbaland south carolina ronaldinho britney spears speed muffins paris hilton paul potts funny music 2007 fergie robot berkeley hilarious

User: teamriras

Avandia and Heart Complications Annals of Medical School description of how Avandia (Rosiglitazone), a medication for type II diabetes, has recently been under scrutiny for possibly increasing deaths from heart attacks and other heart complications. It describes a recent study in the New England Journal of Medicine on the effects of this thiazolinedione (TZD) drug and its mechanism of action. www.annalsofmedicalschool.blogspot.com Tags: Avandia rosiglitazone thiazolinedione TZD type II diabetes medicine heart attack

User: phillipslaw8888

AVANDIA LAWYER Recent medical studies have indicated that the use of the drug AVANDIA® causes an increased risk of Heart Attack or Stroke. If you of a loved one have taken AVANDIA® and suffered a Heart Attack or Stroke, please call us right now. SERIOUS INJURY LAWYERS. Tags: avandia lawyer attorney lawsuit medication diabetes

User: USFoodandDrugAdmin

Stronger Warnings on Avandia and Certain Diabetes Drugs The manufacturers of thiazolidinedione drugs have strengthened warnings about the risks of heart failure with these medications, which are use to treat type 2 diabetes. They are sold as Avandia (rosiglitazone maleate), Avandaryl (rosiglitazone maleate and glimepiride), and Avandamet (rosiglitazone maleate and metformin hydrochloride), which all contain rosiglitazone, and Actos (pioglitazone hydrochloride), Duetact (pioglitazone hydrochloride and glimepride) and Actoplus met, which all contain pioglitazone. The drug labels already had information about heart failure risk, but now there is a new boxed warning that re-emphasizes that these drugs may cause or worsen heart failure in certain patients, and stresses the importance of carefully monitoring patients for signs of heart failure. The labeling recommends that after starting thiazolidinedione therapy or increasing the dose, patients should be observed carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema. If any of these signs and symptoms develop and heart failure is confirmed, practitioners should start appropriate management of the heart failure and consider stopping or reducing the dose of the drug. The boxed warning also notes that these drugs are not recommended for patients with symptomatic heart failure, and are specifically contraindicated in patients with NYHA Class III or IV heart failure. FDA Patient Safety News: October 2007 For more information, please see our website: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=68#2 Tags: Avandia Actos pioglitazone rosiglitazone diabetes heart failure

User: Scotsman22

Re:Vioxx, Avandia, Aspartame,Orobilix,Thalidomide How the FDA Rolls over for corporate money ie Big Pharma Glaxo, Monsanto,Roche, Burroughs-Wellcome, Smith Kline, Eli Lilly, Schering-Plough, ICI-Imperial Chemical, Ciba-Geigy.What happens? autism, AIDS, HIV,Mercury,Lead, Fluoride, Thalidomide Tags: FDA Big Pharma Fraud Morbidity and Mortality LD-50 Birth defects

User: WestConner

Avandia Avandia For more information, visit MedicineCoach.com Tags: avandia rosiglitazone type diabetes blood sugar heart failure pharmacy prescription west conner medicinecoach

User: LawsuitGuru

Ongoing Safety Analysis for Avandia (Aug. 2007) UPDATE: The FDA's Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management Advisory Committees met on July 30, 2007 to discuss the cardiovascular ischemic/thrombosis risks of thiazolidinedione drugs, with focus on rosiglitazone, as presented by FDA and GlaxoSmithKline. For more information about the meeting, see "Additional Information" link below. FDA is continuing to review safety data on the drug rosiglitazone maleate. Some of these data suggest that rosiglitazone may increase a patient's risk of heart attack and heart-related deaths compared with other drugs that also treat type 2 diabetes. Rosiglitazone is sold as Avandia, Avandamet and Avandaryl. A pooled analysis of 42 clinical studies provided by the manufacturer suggested that patients receiving short-term treatment with rosiglitazone may have a 30-40 percent greater risk of heart attack and other cardiovascular events compared with placebo or other anti-diabetic therapy. However, other published and unpublished data from long-term clinical trials provide contradictory evidence about the risk. It is uncertain at this point whether taking rosiglitazone does increase the risk of these adverse events and if so, by how much. It is also not clear whether pioglitazone, the other approved product in the same drug class, may pose the same risk. Also, switching diabetic patients from one drug to another carries its own inherent risk. Healthcare professionals should consider these factors when deciding about treatment for their diabetic patients. FDA's review of all the available data is continuing. Additional Information: FDA MedWatch Safety Alert. Avandia (rosiglitazone). May 21, 2007. http://www.fda.gov/medwatch/safety/2007/safety07.htm#Avandia FDA/Center for Drug Evaluation and Research. Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, July 30, 2007. Draft Agenda. http://www.fda.gov/ohrms/dockets/ac/07/agenda/2007-4308a-agenda-draft.pdf FDA/Center for Drug Evaluation and Research. Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, July 30, 2007. Briefing Information. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-00-index.htm FDA MedWatch Safety Alert. Avandia (rosiglitazone maleate) Tablets, Actos (pioglitazone hydrochloride) Tablets, Avandaryl (rosiglitazone maleate and glimepiride) Tablets... August 14, 2007. http://www.fda.gov/medwatch/safety/2007/safety07.htm#rosi_pio Tags: Avandia FDA Patient Safety Rosiglitazone Heart Attack Drug Reaction Diabetes

User: LawsuitGuru

Avandia and Diabetic Macular Edema (March 2006) Glaxo SmithKline has notified health professionals about reports of diabetic macular edema in patients receiving Avandia (rosiglitazone maleate) which is used to treat type 2 diabetes. These reports involved both new cases of macular edema and worsening of existing cases. In the majority of instances, patients also reported concurrent peripheral edema. In some cases, the macular edema resolved or improved when the drug was discontinued, and in one case it resolved after the dose was reduced. Additional Information: FDA MedWatch Safety Alert -- Avandia (rosiglitazone maleate) Avandamet (rosiglitazone maleate/metformin HCl). January 5, 2006. http://www.fda.gov/medwatch/safety/2006/safety06.htm#Avandia Tags: Avandia Diabetis Diabetic Macular Edema FDA Drug Reaction

User: rmvmedia

AVANDIA WE CAN MAKE CALLS TO 1-800-DERECHOS RING IN YOUR OFFICE, RUN MASS TORTS CAMPAIGNS IN YOUR LOCAL HISPANIC MARKET WE CAN CUSTOMIZE ADS, NEGOTIATE YOUR MEDIA BUY,EVEN PROVIDE A SPANISH CALL CENTER.FOR MORE INFORMATION CALL: 407-767-1615 Tags: ABOGADO AVANDIA DERECHOS HISPANIC LAWYER DIABETES TORTS JUSTICE

User: MedPageToday

Avandia: Pros and Cons http://www.medpagetoday.com CHICAGO -- In the month since the New England Journal of Medicine published a meta-analysis that linked use of rosiglitazone (Avandia) to an increased risk of myocardial infarction, controversy surrounding the use of this popular diabetes drug has continued unabated. Earlier this month a Congressional hearing investigated the FDA's handling of rosiglitazone and several medical journals have weighed in with editorials on the controversy. The American Diabetes Association addressed the issue at a special symposium. MedPage Today examines both sides of the controversy in this exclusive report from Multimedia Producer Greg Laub, with Crystal Phend, MedPage Today staff writer and Neil Osterweil, MedPage Today Senior Associate Editor. Tags: medicine health

User: anymonus777

Is Avandia the next Vioxx? During the 5 year time period between 1999-2004 Vioxx managed to kill 24.600-55.600 people. The drug was marketed by the Merck Corporation for conditions like chronic pain and osteoarthritis. There is now good evidence that Merck knew of these dangers long before the drug was terminated and decided in spite of that to continue to sell it. 3 years before Merck pulled the Drug, they did a study on the safety of Vioxx called APPROVe. When the preliminary studies showed that Vioxx users were twice as likely to have a heart attack Merck's response is unbelievable. Merck decide not to follow the leads but instead they terminate the study. The APPROVe study was not the only study where there were evidence of Vioxx causing heart attacks. Pre approval trials came up with a staggering 8-fold increase in heart attacks. Now in a study published by the New England Journal of Medicine. The anti-diabetic drug Avandia (marketed by GlaxoSmithKline) is being linked to a 45% increase in heart attacks. Is Avandia the next Vioxx? Let us hope not. Links http://www.msnbc.msn.com/id/18783816 http://www.bloomberg.com/apps/news?pid=20601102&sid=akBQMrO_tE0g&refer=uk http://www.forbes.com/home/sciencesandmedicine/2007/05/21/avandia-gsk-diabetes-biz-sci_cx_mh_0521glaxo.html Tags: Avandia Glaxosmithkline Vioxx Merck Diabetes Big Pharma Rx Drugs

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20